We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.

Stay informed

Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.



Event When

Jefferies Healthcare Conference

June 7-9, 2023

Goldman Sachs Global Healthcare Conference

June 12-15, 2023

Citi European Healthcare Conference

June 20-21, 2023

J.P. Morgan European Healthcare Conference

June 22, 2023

Stifel European Healthcare Summit 

June 29-30, 2023

Half-Year 2023 Financial Results reporting*

July 25, 2023

Citi BioPharma Conference

September 6-7, 2023

Morgan Stanley Global Healthcare Conference

September 11-14, 2023

Bank of America Global Healthcare Conference

September 13-14, 2023

Baader Investment Conference

September 18-22, 2023

Nine-Months 2023 Financial Results reporting*

October 24, 2023

Full-Year 2023 Financial Results reporting*

February 6, 2024

*We will be in a silent period for 10 days ahead of the financial reporting.

Financial information

Financial information

The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Read all the latest financial information from Idorsia, including our financial guidance and how the company is funded.

Our strategy

Our strategy

Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.

Development pipeline

Development pipeline

Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.

Corporate reports

Corporate reports

The company publishes a Half Year and Annual Report report summarizing its operational and financial performance, starting its financial year on January 01.

Stock information

Stock information

The registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange on June 16, 2017 (symbol: IDIA). Get all the latest information about our stock, interact with charting tools, and see what the covering analysts think about the company's future performance.



Andrew C. Weiss

Senior Vice President, Head of Investor Relations and Corporate Communications